Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: Effect of higher initial enhancement thresholds on diagnostic performance

Investigative Radiology

Volumn 43, Issue 4, 2008, Pages 236-242

  Sardanelli, Francesco ^a   Fausto, Alfonso ^a   Esseridou, Anastassia ^a   Leo, Giovanni Di ^a   Kirchin, Miles A ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Bracco Imaging SpA   (Italy)

Author keywords

Breast neoplasms; Contrast agents; Dynamic studies; Gadobenate dimeglumine; Magnetic resonance imaging

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBENIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; BREAST FIBROSIS; BREAST LESION; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; INTRADUCTAL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 40949154380     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318160678d     Document Type: Article

References (43)

1. Saslow D, Boetes C, Burke W, et al. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89.
2. Heywang-Kobrunner SH, Beck R. Contrast-Enhanced MRI of the Breast. 2nd ed. Berlin: Springer-Verlag; 1995.
3. Sardanelli F, Iozzelli A, Fausto A. Contrast agents and temporal resolution in breast MR imaging. J Exp Clin Cancer Res. 2002;21(Suppl):69-72.
4. Sardanelli F, Iozzelli A, Fausto A. Breast MR: indications, established technique and new directions. Eur Radiol. 2003;13(Suppl 3):N28-N36.
5. Heywang-Kobrunner SH, Viehweg P, Heinig A, et al. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol. 1997;24:94-108.
6. Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology. 2005;236:789-800.
7. Sardanelli F, Fausto A, Iozzelli A, et al. Dynamic breast magnetic resonance imaging: effect of changing the region of interest on early enhancement using 2D and 3D techniques. J Comput Assist Tomogr. 2004;28:642-646.
8. American College of Radiology (ACR). Breast Imaging Reporting and Data System (BI-RADS) Atlas. 4th ed. Reston, VA: American College of Radiology; 2003.
9. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology. 1999;213:881-888.
10. Baum F, Fischer U, Vosshenrich R, et al. Classification of hypervascularized lesions in CE MR imaging of the breast. Eur Radiol. 2002;12:1087-1092.
11. Sardanelli F, Giuseppetti GM, Panizza P, et al. Sensitivity of MR vs. mammography for detecting foci of multifocal/multicentric breast cancer in fatty and dense breasts using the whole breast pathologic examination as a gold standard. AJR Am J Roentgenol. 2004;183:1149-1157.
12. Sardanelli F, Podo F, D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): Interim results. Radiology. 2007;242:698-715.
13. Heywang SH, Hahn D, Schmidt H, et al. MRI of the breast using gadolinium-DTPA. J Comput Assist Tomogr. 1986;10:199-204.
14. Rieber A, Merkle E, Böhm W, et al. MRI of histologically confirmed mammary carcinoma: clinical relevance of diagnostic procedures for detection of multifocal or contralateral secondary carcinoma. J Comput Assist Tomogr. 1997;21:773-779.
15. Kvistad KA, Rydland J, Vainio J, et al. Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging. Radiology. 2000;216:545-553.
16. Kelcz F, Furman-Haran E, Grobgeld D, et al. Clinical testing of high-spatial-resolution parametric contrast-enhanced MR imaging of the breast. AJR Am J Roentgenol. 2002;179:1485-1492.
17. Jacobs MA, Barker PB, Bluemke DA, et al. Benign and malignant breast lesions: diagnosis with multiparametric MR imaging. Radiology. 2003;229:225-232.
18. Huang W, Fisher PR, Dulaimy K, et al. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology. 2004;232:585-591.
19. Deurloo EE, Klein Zeggelink WF, Teertstra HJ, et al. Contrast-enhanced MRI in breast cancer patients eligible for breast-conserving therapy: complementary value for subgroups of patients. Eur Radiol. 2006;16:692-701.
20. Bazzocchi M, Zuiani C, Panizza P, et al. Contrast-enhanced breast MRI in patients with suspicious microcalcifications on mammography: results of a multicenter trial. AJR Am J Roentgenol. 2006;186:1723-1732.
21. Alderliesten T, Schlief A, Peterse J, et al. Validation of semiautomatic measurement of the extent of breast tumors using contrast-enhanced magnetic resonance imaging. Invest Radiol. 2007;42:42-49.
22. Dao TH, Rahmouni A, Campana F, et al. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology. 1993;187:751-755.
23. Gilles R, Guinebretière JM, Shapeero LG, et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology. 1993;188:473-478.
24. Gilles R, Guinebretière JM, Lucidarme O, et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology. 1994;191:625-631.
25. Gilles R, Guinebretière JM, Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology. 1994;191:633-638.
26. Frouge C, Guinebretière JM, Contesso G, et al. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Invest Radiol. 1994;29:1043-1049.
27. Gilles R, Zafrani B, Guinebretière JM, et al. Ductal carcinoma in situ: MR imaging-histopathologic correlation. Radiology. 1995;196:415-419.
28. Gilles R, Thiollier S, Guinebretiere JM, et al. Diagnosis of local breast cancer recurrences by magnetic resonance imaging. J Gynecol Obstet Biol Reprod. 1995;24:788-793.
29. Gilles R, Meunier M, Lucidarme O, et al. Clustered breast microcalcifications: evaluation by dynamic contrast-enhanced subtraction MRI. J Comput Assist Tomogr. 1996;20:9-14.
30. Kacl GM, Liu P, Debatin JF, et al. Detection of breast cancer with conventional mammography and contrast-enhanced MR imaging. Eur Radiol. 1998;8:194-200.
31. Liu PF, Debatin JF, Caduff RF, et al. Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis. Br J Radiol. 1998;71:501-509.
32. Taïeb S, Ceugnart L, Chevalier A, et al. Value of MRI in symptomatic patients treated with tamoxifen. J Radiol. 2003;84:33-39.
33. Kirchin M, Runge VM. Contrast agent for magnetic resonance imaging: safety update. Top Magn Reson Imaging. 2003;14:426-435.
34. de Haën C, Cabrini M, Akhnana L, et al. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999;23(Suppl 1):S161-S168.
35. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
36. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-221. Erratum Invest Radiol. 2006;41:859.
37. Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine in contrast-enhanced magnetic resonance imaging of the breast: a dose response analysis and comparison with gadopentetate dimeglumine. AJR Am J Roentgenol. 2003;181:663-676.
38. Sardanelli F, Iozzelli A, Fausto A, et al. Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. Radiology. 2005;235:791-797.
39. Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology. 2005;237:45-56.
40. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
41. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228.
42. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; 1991:409-413.
43. Sardanelli F, Quarenghi M. Delayed enhancement of subendocardial infarcted myocardium with gadobenate dimeglumine: a paradoxical effect. Is a double dose too much? Radiology. 2006;240:914-915.